医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ERS Genomics Licenses CRISPR Gene Editing Technology to Daiichi Sankyo to Support Internal Research and Development

2020年01月13日 PM06:53
このエントリーをはてなブックマークに追加


 

DUBLIN

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced the signing of a license agreement with Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan. The agreement provides Daiichi Sankyo with access to CRISPR/Cas9 genome editing technology intellectual property for use in its internal research and development.

ERS Genomics holds an exclusive worldwide license to the foundational intellectual property covering CRISPR/Cas9 for all applications other than use as a human therapeutic. Under the terms of the license, Daiichi Sankyo is able to use CRISPR technology to support its R&D initiatives to address areas of unmet medical need.

Eric Rhodes, CEO of ERS Genomics, said:Daiichi Sankyo is our first large pharma licensee in Japan. CRISPR/Cas9 is revolutionary in genome editing; we look forward to observing how the company applies the technology to further advance its R&D operations.”

Financial details of the agreement are not disclosed.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005370/en/

CONTACT

Media contact for ERS Genomics:

Katie Odgaard

Zyme Communications

Tel: +44(0)7787 502 947

Email: katie.odgaard@zymecommunications.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • iFLYTEK and Hancom Group Launch Accufly.AI to Help Combat the Coronavirus Pandemic
  • Jack Ma Foundation and Alibaba Foundation Donation Arrives in Laos to Combat Covid-19
  • PreCheck Announces Exclusive Distribution Agreements for Coronavirus (COVID-19) PCR Test in Afghanistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan
  • Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
  • 知临集团与Covar医疗携手依托现有Smart-ACTTM平台和Acticule传染病平台研究至少3种2019冠状病毒肺炎(COVID-19)候选再利用药物(SACT-COV19)